UB Paderborn / Katalog / Suche / in CDI

Dabrafenib in BRAF -mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

The Lancet (British edition), 2012-07, Vol.380 (9839), p.358-365

2012

Link zum Volltext

Verfügbarkeit prüfen

Melanoma arising in a Giant congenital melanocytic nevus: two case reports

Diagnostic pathology, 2019-02, Vol.14 (1), p.21-21, Article 21

2019

Link zum Volltext

Verfügbarkeit prüfen

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

The New England journal of medicine, 2012-07, Vol.367 (2), p.107-114

2012

Link zum Volltext

Verfügbarkeit prüfen

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials

European journal of cancer (1990), 2020-01, Vol.125, p.114-120

2020

Link zum Volltext

Verfügbarkeit prüfen

Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation р.T632I

Case reports in oncology, 2019-01, Vol.12 (1), p.109-112

2019

Link zum Volltext

Verfügbarkeit prüfen

Hypercoagulability as a prognostic factor for survival in patients with metastatic renal cell carcinoma

Journal of experimental & clinical cancer research, 2009-03, Vol.28 (1), p.30-30, Article 30

2009

Link zum Volltext

Verfügbarkeit prüfen

Immunological monitoring for prediction of clinical response to antitumor vaccine therapy

Oncotarget, 2018-05, Vol.9 (36), p.24381-24390

2018

Link zum Volltext

Verfügbarkeit prüfen

Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I

Case reports in oncology, 2019-01, Vol.12 (1), p.109-112

2019

Link zum Volltext

Verfügbarkeit prüfen

The immunologic patterns of response to immunotherapy

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e14502-e14502

Borunova, Anna A.

2016

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of treatment patterns in patients with BRAF-mutant cutaneous melanoma in adjuvant setting in real practice

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e21573-e21573

2022

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant fermented wheat germ extract (Avemar) nutraceutical improves survival of high-risk skin melanoma patients: a randomized, pilot, phase II clinical study with a 7-year follow-up

Cancer biotherapy & radiopharmaceuticals, 2008-08, Vol.23 (4), p.477

2008

Link zum Volltext

Verfügbarkeit prüfen

Intralesional anti-PD1 treatment in patients with metastatic melanoma: The pilot study

Journal of clinical oncology, 2018-02, Vol.36 (5_suppl), p.188-188

2018

Link zum Volltext

Verfügbarkeit prüfen

Cancer/testis genes expression in human melanoma cell lines

Melanoma research, 2008-10, Vol.18 (5), p.303-313

2008

Link zum Volltext

Verfügbarkeit prüfen

The role of surgery (metastasectomy) in advanced BRAF positive melanoma during modern therapy

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e21512-e21512

2022

Link zum Volltext

Verfügbarkeit prüfen

Treatment with tebentafusp beyond radiographic progressive disease (PD) in metastatic uveal melanoma (mUM)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9585-9585

2022

Link zum Volltext

Verfügbarkeit prüfen

Multicenter prospective clinical trial of molecular genetic markers for non-invasive differential diagnosis of benign and malignant melanocytic skin lesions

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e21581-e21581

2022

Link zum Volltext

Verfügbarkeit prüfen

Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): Primary results of COMBI-APlus

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9525-9525

2021

Link zum Volltext

Verfügbarkeit prüfen

Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAF V600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9547-9547

2022

Link zum Volltext

Verfügbarkeit prüfen

Recurrence-free survival (RFS) and objective response rate (ORR) phase 1/2 study of intralesional (IL) neoadjuvant (neo) anti-PD1 agents (aPD1) for stage IIIB-IV melanoma (MEL)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14171-e14171

2019

Link zum Volltext

Verfügbarkeit prüfen

One-year (yr) recurrence-free survival (RFS) from a randomized, open label phase II study of neoadjuvant (neo) talimogene laherparepvec (T-VEC) plus surgery (surgx) versus surgx for resectable stage IIIB-IVM1a melanoma (MEL)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9520-9520

2019

Link zum Volltext

Verfügbarkeit prüfen

The prevalence of Merkel cell polyomavirus in Russian patients with Merkel cell carcinoma

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e21605-e21605

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Outcomes in Patients With BRAFV600-Mutant Metastatic Melanoma Receiving Dabrafenib Monotherapy: Analysis From Phase 2 and 3 Clinical Trials

European journal of cancer (1990), 2020-01, Vol.125, p.114-120

2020

Link zum Volltext

Verfügbarkeit prüfen

Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9508-9508

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial (BCD-100-2/MIRACULUM) of the novel PD-1 inhibitor (BCD-100) in patients with advanced melanoma

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9549-9549

2019

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Dabrafenib in BRAF -mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Melanoma arising in a Giant congenital melanocytic nevus: two case reports

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials

Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation р.T632I

Hypercoagulability as a prognostic factor for survival in patients with metastatic renal cell carcinoma

Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE)

Immunological monitoring for prediction of clinical response to antitumor vaccine therapy

Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I

The immunologic patterns of response to immunotherapy

Evaluation of treatment patterns in patients with BRAF-mutant cutaneous melanoma in adjuvant setting in real practice

Adjuvant fermented wheat germ extract (Avemar) nutraceutical improves survival of high-risk skin melanoma patients: a randomized, pilot, phase II clinical study with a 7-year follow-up

Intralesional anti-PD1 treatment in patients with metastatic melanoma: The pilot study

Cancer/testis genes expression in human melanoma cell lines

The role of surgery (metastasectomy) in advanced BRAF positive melanoma during modern therapy

Treatment with tebentafusp beyond radiographic progressive disease (PD) in metastatic uveal melanoma (mUM)

Multicenter prospective clinical trial of molecular genetic markers for non-invasive differential diagnosis of benign and malignant melanocytic skin lesions

Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): Primary results of COMBI-APlus

Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAF V600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study

Recurrence-free survival (RFS) and objective response rate (ORR) phase 1/2 study of intralesional (IL) neoadjuvant (neo) anti-PD1 agents (aPD1) for stage IIIB-IV melanoma (MEL)

One-year (yr) recurrence-free survival (RFS) from a randomized, open label phase II study of neoadjuvant (neo) talimogene laherparepvec (T-VEC) plus surgery (surgx) versus surgx for resectable stage IIIB-IVM1a melanoma (MEL)

The prevalence of Merkel cell polyomavirus in Russian patients with Merkel cell carcinoma

Long-Term Outcomes in Patients With BRAFV600-Mutant Metastatic Melanoma Receiving Dabrafenib Monotherapy: Analysis From Phase 2 and 3 Clinical Trials

Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL)

Phase II trial (BCD-100-2/MIRACULUM) of the novel PD-1 inhibitor (BCD-100) in patients with advanced melanoma

Suchergebnisse filtern